Indian drugmaker, Ranbaxy is planning to expand its business in the US and capture a share in emerging markets.
Subscribe to our email newsletter
Ranbaxy wants to go ahead with its expansion plans though American regulators blocked imports of company’s 31 medicines over quality issues.
The company is also considering to start selling a recently approved generic version of acne drug Accutane in about six months.
Ranbaxy CEO Arun Sawhney was quoted by The Aossciate Press as saying that "the US, as a total business, will remain the most important to us."
The company is also working to expand generic sales in emerging markets such as India, China, Brazil and Russia.